EUVIMEDEUVIMED entdecken
Open Access

Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes

Jian-Jun Liu, Jianhong Ching, Hai Ning Wee, Sylvia Liu, Resham L Gurung, Janus Lee, Yiamunaa M, Huili Zheng, Lye Siang Lee, Keven Ang, Yi Ming Shao, Jean-Paul Kovalik und 5 weitere

Diabetes Care · 01.12.2023 · 46 (12) · 2223-2231

DOI: 10.2337/dc23-1147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 05.10.2023. Verfasst von Jian-Jun Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Unit, Khoo Teck Puat Hospital, Singapore. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Kidney Failure, Chronic. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Khoo Teck Puat Hospital STAR Grant, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE We sought to study the associations between plasma metabolites in the tryptophan-kynurenine pathway and the risk of progression to end-stage kidney disease (ESKD) in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Plasma tryptophan, kynurenine, 3-hydroxykynurenine, kynurenic acid, and xanthurenic acid concentrations were measured in discovery (n = 1,915) and replication (n = 346) cohorts. External validation was performed in Chronic Renal Insufficiency Cohort (CRIC) participants with diabetes (n = 1,312). The primary outcome was a composite of incident ESKD (progression to estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m2, sustained dialysis, or renal death). The secondary outcome was annual eGFR decline. RESULTS In the discovery cohort, tryptophan was inversely associated with risk for ESKD, and kynurenine-to-tryptophan ratio (KTR) was positively associated with risk for ESKD after adjustment for clinical risk factors, including baseline eGFR and albuminuria (adjusted hazard ratios [HRs] 0.62 [95% CI 0.51, 0.75] and 1.48 [1.20, 1.84] per 1 SD). High levels of kynurenic acid and xanthurenic acid were associated with low risks of ESKD (0.74 [0.60, 0.91] and 0.74 [0.60, 0.91]). Consistently, high levels of tryptophan, kynurenic acid, and xanthurenic acid were independently associated with a slower eGFR decline, while a high KTR was predictive of a faster eGFR decline. Similar outcomes were obtained in the replication cohort. Furthermore, the inverse association between kynurenic acid and risk of ESKD was externally validated in CRIC participants with diabetes (adjusted HR 0.78 [0.65, 0.93]). CONCLUSIONS Accelerated catabolism of tryptophan in the kynurenine pathway may be involved in progressive loss of kidney function. However, shunting the kynurenine pathway toward the kynurenic acid branch may potentially slow renal progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Kidney Failure, ChronicHumansKynurenineTryptophanKynurenic AcidDisease Progression

Substanzen

KynurenineTryptophanKynurenic Acid

Autor:innen und Institutionen

  • Clinical Research Unit, Khoo Teck Puat Hospital, Singapore.
  • Duke-NUS Medical School, Singapore.
  • Diabetes Center, Admiralty Medical Center, Khoo Teck Puat Hospital, Singapore.
  • Center for Precision Medicine, The University of Texas Health, San Antonio, TX.
  • Division of Nephrology, Department of Medicine, The University of Texas Health, San Antonio, TX.
  • Kidney Research Institute, Seattle, WA.

ORCID-Profile: Su Chi Lim

Förderung

  • Khoo Teck Puat Hospital STAR Grant
  • National Medical Research Council

Zitieren

APA

Liu, J. J., Ching, J., Wee, H. N., Liu, S., Gurung, R. L., Lee, J., M, Y., Zheng, H., Lee, L. S., Ang, K., Shao, Y. M., Kovalik, J. P., Subramaniam, T., Sum, C. F., Sharma, K., Kestenbaum, B. R., & Lim, S. C. (2023). Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care, 46(12), 2223-2231. https://doi.org/10.2337/dc23-1147

Vancouver

Liu JJ, Ching J, Wee HN, Liu S, Gurung RL, Lee J, et al. Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care. 2023;46(12):2223-2231. doi:10.2337/dc23-1147

BibTeX
@article{Liu2023,
  author = {Liu, Jian-Jun and Ching, Jianhong and Wee, Hai Ning and Liu, Sylvia and Gurung, Resham L and Lee, Janus and M, Yiamunaa and Zheng, Huili and Lee, Lye Siang and Ang, Keven and Shao, Yi Ming and Kovalik, Jean-Paul and Subramaniam, Tavintharan and Sum, Chee Fang and Sharma, Kumar and Kestenbaum, Bryan R and Lim, Su Chi},
  title = {Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes},
  journal = {Diabetes Care},
  year = {2023},
  volume = {46},
  number = {12},
  pages = {2223--2231},
  doi = {10.2337/dc23-1147}
}
Kostenlos starten →